Cody J Lensing1, Katie T Freeman1, Sathya M Schnell1, Robert C Speth2,3, Adam T Zarth1,4, Carrie Haskell-Luevano1. 1. Department of Medicinal Chemistry and Institute for Translational Neuroscience , University of Minnesota , 308 Harvard Street SE , Minneapolis , Minnesota 55455 , United States. 2. College of Pharmacy , Nova Southeastern University , Fort Lauderdale , Florida 33328-2018 , United States. 3. Department of Pharmacology and Physiology , Georgetown University , Washington, D.C. 20057 , United States. 4. Masonic Cancer Center , University of Minnesota , 2231 Sixth Street SE, 2-210 CCRB , Minneapolis , Minnesota 55455 , United States.
Abstract
Understanding the functional relevance of G protein-coupled receptor (GPCR) homodimerization has been limited by the insufficient tools to assess asymmetric signaling occurring within dimers comprised of the same receptor type. We present unmatched bivalent ligands (UmBLs) to study the asymmetric function of melanocortin homodimers. UmBLs contain one agonist and one antagonist pharmacophore designed to target a melanocortin homodimer such that one receptor is occupied by an agonist and the other receptor by an antagonist pharmacophore. First-in-class biased UmBLs (BUmBLs) targeting the human melanocortin-4 receptor (hMC4R) were discovered. The BUmBLs displayed biased agonism by potently stimulating cAMP signaling (EC50 ∼ 2-6 nM) but minimally activating the β-arrestin recruitment pathway (≤55% maximum signal at 10 μM). To our knowledge, we report the first single-compound strategy to pharmacologically target melanocortin receptor allosteric signaling that occurs between homodimers that can be applied straightforwardly in vitro and in vivo to other GPCR systems.
Understanding the functional relevance of G protein-coupled receptor (n class="Gene">GPCR) homodimerization has been limited by the insufficient tools to assess asymmetric signaling occurring within dimers comprised of the same receptor type. We present unmatched bivalent ligands (UmBLs) to study the asymmetric function of melanocortin homodimers. UmBLs contain one agonist and one antagonist pharmacophore designed to target a melanocortin homodimer such that one receptor is occupied by an agonist and the other receptor by an antagonist pharmacophore. First-in-class biased UmBLs (BUmBLs) targeting the humanmelanocortin-4 receptor (hMC4R) were discovered. The BUmBLs displayed biased agonism by potently stimulating cAMP signaling (EC50 ∼ 2-6 nM) but minimally activating the β-arrestin recruitment pathway (≤55% maximum signal at 10 μM). To our knowledge, we report the first single-compound strategy to pharmacologically target melanocortin receptor allosteric signaling that occurs between homodimers that can be applied straightforwardly in vitro and in vivo to other GPCR systems.
Authors: Dilani Chathurika Dehigaspitiya; Bobbi L Anglin; Kara R Smith; Craig S Weber; Ronald M Lynch; Eugene A Mash Journal: Org Biomol Chem Date: 2015-10-13 Impact factor: 3.876
Authors: Katlyn A Fleming; Mark D Ericson; Katie T Freeman; Danielle N Adank; Mary M Lunzer; Stacey L Wilber; Carrie Haskell-Luevano Journal: ACS Chem Neurosci Date: 2018-02-13 Impact factor: 4.418
Authors: Dilani Chathurika Dehigaspitiya; Suryakiran Navath; Craig S Weber; Ronald M Lynch; Eugene A Mash Journal: Tetrahedron Lett Date: 2015-06-03 Impact factor: 2.415
Authors: A S Chen; D J Marsh; M E Trumbauer; E G Frazier; X M Guan; H Yu; C I Rosenblum; A Vongs; Y Feng; L Cao; J M Metzger; A M Strack; R E Camacho; T N Mellin; C N Nunes; W Min; J Fisher; S Gopal-Truter; D E MacIntyre; H Y Chen; L H Van der Ploeg Journal: Nat Genet Date: 2000-09 Impact factor: 38.330
Authors: Julia Kühhorn; Angela Götz; Harald Hübner; Dawn Thompson; Jennifer Whistler; Peter Gmeiner Journal: J Med Chem Date: 2011-10-31 Impact factor: 7.446
Authors: Eyup Akgün; Muhammad I Javed; Mary M Lunzer; Michael D Powers; Yuk Y Sham; Yoshikazu Watanabe; Philip S Portoghese Journal: J Med Chem Date: 2015-10-20 Impact factor: 7.446
Authors: Nicolas Heyder; Gunnar Kleinau; Michal Szczepek; Dennis Kwiatkowski; David Speck; Lucia Soletto; José Miguel Cerdá-Reverter; Heiko Krude; Peter Kühnen; Heike Biebermann; Patrick Scheerer Journal: Front Endocrinol (Lausanne) Date: 2019-07-31 Impact factor: 5.555